Form 4: Tyra Biosciences Director Sells $2.5M in Stock

Tyra Biosciences Director Gilla Kaplan exercised stock options and subsequently sold over 67,000 shares of common stock for approximately $2.5 million.

Summary

• Gilla Kaplan, a Director at Tyra Biosciences, Inc., executed a series of transactions involving the exercise of stock options and the subsequent sale of common stock.
• On March 25, 2026, Kaplan acquired 14,295 shares of common stock by exercising options at $2.25 per share and immediately sold these shares at a weighted average price of $36.9714 per share.
• On March 26, 2026, Kaplan acquired an additional 53,172 shares of common stock by exercising options at $2.25 per share and subsequently sold these shares at a weighted average price of $37.7483 per share.
• Following these transactions, Kaplan's direct beneficial ownership of common stock in Tyra Biosciences, Inc. stands at 28,231 shares, with no derivative securities remaining.
• The sales were conducted under a Rule 10b5-1 plan.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a moderately negative signal. While the transactions were pre-planned, significant insider selling, especially by a director, can create downward pressure or raise questions about future growth prospects, even if the underlying business remains strong.

Positives

• The exercise of options indicates a significant appreciation in the company's stock price from the option exercise price of $2.25 to the sale prices of approximately $37.
• The transactions were made pursuant to a Rule 10b5-1 plan, indicating a pre-arranged trading strategy rather than an immediate reaction to new information.

Negatives

• A Director selling a substantial number of shares (67,467 shares in total) could be perceived negatively by the market, potentially signaling a lack of confidence or a belief that the stock's current valuation is high.
• The total value of shares sold exceeded $2.5 million, representing a significant disposition of holdings by an insider.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

StockSavvy.ai notes that insider selling, even when pre-arranged under a Rule 10b5-1 plan, can sometimes be interpreted by the market as a signal, particularly in the volatile biotech sector where company-specific news heavily influences stock performance. While not necessarily indicative of negative company performance, significant insider sales warrant investor attention, especially when considering the broader industry trends and competitor valuations.

Comparison to Industry Standards

• This filing reports individual insider transactions and does not provide company-wide financial or operational results that can be directly compared to industry standards or specific competitor projects. StockSavvy.ai cannot make a direct comparison based solely on this Form 4.

Related Party Transactions

• The reported transactions are related party dealings, as they involve a Director of Tyra Biosciences, Inc. exercising stock options and selling company shares.

Stakeholder Impact

• Shareholders: May interpret the significant insider selling as a negative signal, potentially leading to decreased investor confidence or downward pressure on the stock price.
• Employees: No direct impact mentioned, but market reaction could indirectly affect employee morale or stock-based compensation value.

Next Steps

• The Reporting Person undertakes to provide full information regarding the number of shares sold at each separate price within the reported ranges upon request to the Issuer, any security holder, or the SEC staff.

Key Dates

Recommendation

While significant insider selling can be a bearish signal, the transactions were executed under a Rule 10b5-1 plan, suggesting a pre-determined strategy rather than a reaction to new, undisclosed negative information. Investors should hold and monitor future insider activity and company performance, as the underlying business fundamentals are not directly addressed in this filing. A 'sell' recommendation would be premature without further fundamental analysis.

Keywords

Tyra Biosciences, TYRA, Insider Trading, Form 4, Stock Option Exercise, Stock Sale, Director Transaction, Gilla Kaplan, Rule 10b5-1